title: Product listing agreements (PLAs): a new tool for reaching Quebec's pharmaceutical policy objectives?
abstract: Product listing agreements (PLAs) with pharmaceutical manufacturers are increasingly viewed as an innovative and useful tool in the effort to control drug expenditures. To date, Quebec is the only province that has been reluctant to enter into such agreements, arguing that their confidential nature may lead to a disparity in coverage between individuals covered by the public plan and those covered by private insurance. While PLAs may, in fact, present such a risk, in this paper we will argue that when used correctly, these agreements are actually tools that could help attain all four of the objectives set out in Quebec's policy on medications, namely: (a) improved access to drugs, (b) fair and reasonable drug pricing, (c) optimal drug use and (d) maintaining a dynamic biopharmaceutical industry in Quebec.
authors: Professor and Director, Health Law and Policy Programmes, Professor, Faculty of Law, University of Sherbrooke, Sherbrooke, QC.
authors: Mélanie
authors: M
authors: Bourassa Forcier
authors: François
authors: F
authors: Noël
mesh_terms: D002170:Canada; D003363:Cost Control / Q000191:economics / Q000458:organization & administration*; D016527:Drug Costs; D004345:Drug Industry / Q000191:economics / Q000458:organization & administration*; D006291:Health Policy; D006297:Health Services Accessibility / Q000191:economics / Q000458:organization & administration; D006801:Humans; D007348:Insurance, Health / Q000191:economics / Q000458:organization & administration*; D011792:Quebec
references: BMC Health Serv Res. 2010 Jun 07;10:153
references: 20529296
references: Milbank Q. 2007 Sep;85(3):469-98
references: 17718665
references: Cochrane Database Syst Rev. 2008 Apr 16;(2):CD000011
references: 18425859
references: Health Policy. 2010 Aug;96(3):179-90
references: 20226559
references: Health Aff (Millwood). 2011 Dec;30(12):2329-37
references: 22147861